Akèy › Trombositemi Esansyèl
Etid klinik pou Trombositemi Esansyèl ap rekrite nan Etazini
16 etid pou Trombositemi Esansyèl ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- New York City, NY7 etid
- Durham, NC6 etid
- Baltimore, MD4 etid
- Mountain View, CA4 etid
- Boston, MA4 etid
- Nashville, TN4 etid
- Miami, FL4 etid
- Salt Lake City, UT4 etid
- Chicago, IL4 etid
- Cleveland, OH3 etid
- Houston, TX3 etid
- Kansas City, MO3 etid
- St. Louis, MO3 etid
- Los Angeles, CA3 etid
- Columbus, OH3 etid
- Irvine, CA3 etid
Pa eta
- Florid5 etid
- Illinois4 etid
- Kalifòni7 etid
- Kansas3 etid
- Maryland4 etid
- Massachusetts4 etid
- Missouri3 etid
- New York7 etid
- North Carolina8 etid
- Ohio5 etid
- Pennsylvania4 etid
- Tennessee4 etid
- Texas4 etid
- Utah4 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06661915Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT04282187A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07623200A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07008118Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07441694Registry of Older Patients With Cancer
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT06034002A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Apr 2, 2026 · NCT06351631Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 27, 2026 · NCT06063486An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Mar 10, 2026 · NCT05123365MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jan 23, 2026 · NCT07362225Ruxolitinib in Thrombocythemia and Polycythemia Vera
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jan 8, 2026 · NCT04644211MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Dec 17, 2025 · NCT06541249Two Step Haplo With Radiation Conditioning
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 30, 2025 · NCT05031897Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Tout sèks · Mizajou Oct 27, 2025 · NCT01137643Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou May 3, 2024 · NCT06218628Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.